GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Net Current Asset Value

TLPH (Talphera) Net Current Asset Value : $-0.19 (As of Mar. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Talphera Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Talphera's net current asset value per share for the quarter that ended in Mar. 2025 was $-0.19.

The historical rank and industry rank for Talphera's Net Current Asset Value or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Talphera was 22.23. The lowest was 1.04. And the median was 5.78.

TLPH's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.835
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Talphera Net Current Asset Value Historical Data

The historical data trend for Talphera's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Net Current Asset Value Chart

Talphera Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.22 -9.25 -0.13 0.31 -0.05

Talphera Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.23 0.05 -0.05 -0.19

Competitive Comparison of Talphera's Net Current Asset Value

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talphera's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Talphera's Price-to-Net-Current-Asset-Value falls into.


;
;

Talphera Net Current Asset Value Calculation

Talphera's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(9.417-10.235-0-0)/17.029
=-0.05

Talphera's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(6.176-9.396-0-0)/17.098
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talphera  (NAS:TLPH) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Talphera Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Talphera's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Talphera Business Description

Traded in Other Exchanges
Address
1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Executives
Vincent J. Angotti director, officer: Chief Executive Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Raffi Asadorian officer: Chief Financial Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer director, officer: Chief Medical Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko director C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams director C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards director ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Badri N Dasu officer: Chief Engineering Officer C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel officer: Chief Development Officer C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan director, 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger 10 percent owner C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp 10 percent owner
Three Arch Partners Iv Lp 10 percent owner
Three Arch Associates Iv Lp 10 percent owner 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028